SPECC1 and COVID-19: We further demonstrated with FRET assays that TMP1 was 16.8-fold less sensitive to NSP5-E166V mutation when compared with NRV (Fig. 6f), which is a dominant mutation leading to NRV-resistance found in COVID-19 patients45,46.